Rahmoune Hakim, Boutrid Nada
Department of Medicine, LIRSSEI Research Laboratory, Faculty of Medicine, University of Setif-1, Setif 19000, Algeria.
Department of Pediatrics, Setif University Hospital, University of Setif-1, Setif 19000, Algeria.
World J Clin Cases. 2025 Sep 16;13(26):102957. doi: 10.12998/wjcc.v13.i26.102957.
Patients with ulcerative colitis (UC) have an increased risk of thromboembolic events, particularly venous thromboembolism (VTE), which encompasses deep vein thrombosis and pulmonary embolism. The incidence of VTE in patients with UC is significantly higher than that in the general population, and a retrospective cohort study found that patients undergoing colectomy had a notable risk of developing VTE, with rates reaching as high as 22% among patients exposed to tofacitinib within a month prior to surgery. The GETAID FOCUS study also reported a high prevalence of self-reported VTE in patients with UC, with a pooled prevalence of approximately 12% across various studies. The risk of thromboembolism in UC is multifactorial and influenced by chronic inflammation, a wide range of medications used, potential surgical interventions, and possibly genetic factors or associations that are yet to be fully defined. Recognizing the various contributing factors is crucial for developing effective preventive strategies and improving patient outcomes.
溃疡性结肠炎(UC)患者发生血栓栓塞事件的风险增加,尤其是静脉血栓栓塞(VTE),其包括深静脉血栓形成和肺栓塞。UC患者中VTE的发生率显著高于普通人群,一项回顾性队列研究发现,接受结肠切除术的患者发生VTE的风险显著,在术前一个月内使用托法替布的患者中,发生率高达22%。GETAID FOCUS研究还报告称,UC患者自我报告的VTE患病率较高,各项研究的汇总患病率约为12%。UC中血栓栓塞的风险是多因素的,受慢性炎症、广泛使用的各种药物、潜在的手术干预以及可能尚未完全明确的遗传因素或关联的影响。认识到各种促成因素对于制定有效的预防策略和改善患者预后至关重要。